Reviewer's report

Title: Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial

Version: 2 Date: 24 August 2012

Reviewer: Hidefumi Wada

Reviewer's report:

Discretionary Revisions;
Comments to the Author
I have read your article with great interest. I have a minor point of concern:

This manuscript reported that an exploratory, prospective, open-label clinical trial was conducted in 12 patients with mycosis fungoides. This paper gives us the quite important information of a novel synergic IFN mixture (HeberPAG®) for pharmacokinetic and pharmacodynamic studies. To publish this manuscript, I want to know some additional data of the enrolled patients.

Minor revision
1) A limited number of patients were enrolled in this study. However, the author should describe the data of each patients in more details, such as the prior systemic treatments (PUVA, radiation, IFN-g, CHOP therapy etc), laboratory data (WBC, LDH, sIL-2R, etc). This information will be more helpful for the readers.

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:
'I declare that I have no competing interests'